Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

AB7356 Anti-von Willebrand Factor Antibody

AB7356
100 µg  
Purchase on Sigma-Aldrich

Special Offers

Overview

Replacement Information

Key Spec Table

Species ReactivityKey ApplicationsHostFormatAntibody Type
H, M, RELISA, IH(P), WBRbPurifiedPolyclonal Antibody
Description
Catalogue NumberAB7356
Brand Family Chemicon®
Trade Name
  • Chemicon
DescriptionAnti-von Willebrand Factor Antibody
Alternate Names
  • Factor VIII Related Antigen
Background Informationvon Willebrand factor (UniProt: P04275; also known as vWF) is encoded by the VWF (also known as F8VWF) gene (Gene ID:7450) in human. vWF is a multimeric plasma glycoprotein that is synthesized by endothelial cells and plays an important in the maintenance of hemostasis. It is synthesized with a signal peptide (aa 1-22), which is subsequently cleaved off in the mature form. vWF is known to promote adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. vWF also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. Mutations in VWF gene are linked to von Willebrand diseases 1-3 that are common hemorrhagic disorders caused by impaired platelet aggregation. Two isoforms of vWF have been described that are produced by alternative splicing.
References
Product Information
FormatPurified
PresentationPurified rabbit immunoglobulin in buffer containing 0.02 M PBS pH 7.6, 0.25 M NaCl with 0.1% sodium azide.
Quality LevelMQ100
Applications
ApplicationAnti-von Willebrand Factor, Cat. No. AB7356, is a rabbit polyclonal antibody that detects von Willebrand Factor and has been tested for use in ELISA, Immunohistochemistry, and Western Blotting.
Key Applications
  • ELISA
  • Immunohistochemistry (Paraffin)
  • Western Blotting
Application NotesImmunohistochemistry Analysis: A representative lot detected von Willebrand Factor in Immunohistochemistry applications.

ELISA Analysis: A representative lot detected von Willebrand Factor in ELISA applications.

Immunohistochemistry Analysis: A 1:250-1,000 dilution from a representative lot detected von Willebrand Factor in human cerebral cortex, mouse hippocampus, rat cerebellum and human tonsil tissue sections.
Biological Information
ImmunogenHuman von Willebrand Factor purified from plasma.
ConcentrationPlease refer to the Certificate of Analysis for the lot-specific concentration.
HostRabbit
SpecificityAB7356 is specific for vWF by ELISA against the human protein and by immunohistochemistry. The antibody is reactive in paraffin embedded tissues on human, rat, and mouse. Other species not tested. Antibody has not been evaluated by western blot analysis for reactivity to vWF.
Species Reactivity
  • Human
  • Mouse
  • Rat
Antibody TypePolyclonal Antibody
Entrez Gene Number
Entrez Gene SummaryThe glycoprotein encoded by this gene functions as both an antihemophilic factor carrier and a platelet-vessel wall mediator in the blood coagulation system. It is crucial to the hemostasis process. Mutations in this gene or deficiencies in this protein result in von Willebrand's disease. An unprocessed pseudogene has been found on chromosome 22.
Gene Symbol
  • VWF
  • F8VWF
  • F8
  • vWF
  • VWD
Purification MethodProtein A Purfied
UniProt Number
UniProt SummaryFUNCTION: SwissProt: P04275 # Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
SIZE: 2813 amino acids; 309299 Da
SUBUNIT: Multimeric. Interacts with F8.
SUBCELLULAR LOCATION: Secreted. Note=Localized to storage granules.
TISSUE SPECIFICITY: Plasma.
DOMAIN: SwissProt: P04275 The von Willebrand antigen 2 is required for multimerization of VWF and for its targeting to storage granules.
PTM: All cysteine residues are involved in intrachain or interchain disulfide bonds.
DISEASE: SwissProt: P04275 # Defects in VWF are associated with various forms of von Willebrand disease (VWD) [MIM:193400, 277480]. VWD is characterized by frequent bleeding (gingival, minor skin quantitative lacerations, menorrhagia, etc.). Type I VWD is associated with a deficiency of VWF; type II by normal to decreased plasma level of VWF; type III by a virtual absence of VWF. There are subtypes (A to H) of type II VWD; for example: type IIA is characterized by the absence of VWF high molecular weight multimers in plasma.
SIMILARITY: Contains 1 CTCK (C-terminal cystine knot-like) domain. & Contains 4 TIL (trypsin inhibitory-like) domains. & Contains 3 VWFA domains. & Contains 3 VWFC domains. & Contains 4 VWFD domains.
Molecular Weight~250 kDa observed; 309.26 kDa calculated. Uncharacterized bands may be observed in some lysate(s).
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality AssuranceImmunohistochemistry(paraffin):
Representative images from a previous lot.
Rabbit anti-vWF (AB7356) staining of Human Cerebral Cortex. Tissue pretreated with Citrate Buffer, ph 6.0, anti-vWF at 20 μg/mL, IHC-Select Detection with HRP-DAB.
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage ConditionsStable for 1 year at 2-8ºC from date of receipt.
Packaging Information
Material Size100 µg
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
AB7356 04053252506710

Documentation

Protocols

Title
AB7356 IH(P) Summary
IHC Select Paraffin Protocol

Anti-von Willebrand Factor Antibody SDS

Title

Safety Data Sheet (SDS) 

Anti-von Willebrand Factor Antibody Certificates of Analysis

TitleLot Number
Anti-von Willebrand Factor - 2142168 2142168
Anti-von Willebrand Factor - 2428720 2428720
Anti-von Willebrand Factor - 2455686 2455686
Anti-von Willebrand Factor - 1987046 1987046
Anti-von Willebrand Factor - 2064704 2064704
Anti-von Willebrand Factor - 2279535 2279535
Anti-von Willebrand Factor - 2489066 2489066
Anti-von Willebrand Factor - 3239865 3239865
Anti-von Willebrand Factor - 3455235 3455235
Anti-von Willebrand Factor - 3691360 3691360

References

Reference overviewApplicationSpeciesPub Med ID
Maternal anti-platelet β3 integrins impair angiogenesis and cause intracranial hemorrhage.
Yougbaré, I; Lang, S; Yang, H; Chen, P; Zhao, X; Tai, WS; Zdravic, D; Vadasz, B; Li, C; Piran, S; Marshall, A; Zhu, G; Tiller, H; Killie, MK; Boyd, S; Leong-Poi, H; Wen, XY; Skogen, B; Adamson, SL; Freedman, J; Ni, H
The Journal of clinical investigation  125  1545-56  2015

Show Abstract
25774504 25774504
A tissue-engineered humanized xenograft model of human breast cancer metastasis to bone.
Thibaudeau, L; Taubenberger, AV; Holzapfel, BM; Quent, VM; Fuehrmann, T; Hesami, P; Brown, TD; Dalton, PD; Power, CA; Hollier, BG; Hutmacher, DW
Disease models & mechanisms  7  299-309  2014

Show Abstract
24713276 24713276
Antagonizing the αv β3 integrin inhibits angiogenesis and impairs woven but not lamellar bone formation induced by mechanical loading.
Tomlinson, RE; Schmieder, AH; Quirk, JD; Lanza, GM; Silva, MJ
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research  29  1970-80  2014

Show Abstract
24644077 24644077
Multiphasic construct studied in an ectopic osteochondral defect model.
Jeon, JE; Vaquette, C; Theodoropoulos, C; Klein, TJ; Hutmacher, DW
Journal of the Royal Society, Interface / the Royal Society  11  20140184  2014

Show Abstract
24694896 24694896
Multi-omic integrated networks connect DNA methylation and miRNA with skeletal muscle plasticity to chronic exercise in Type 2 diabetic obesity.
Rowlands, DS; Page, RA; Sukala, WR; Giri, M; Ghimbovschi, SD; Hayat, I; Cheema, BS; Lys, I; Leikis, M; Sheard, PW; Wakefield, SJ; Breier, B; Hathout, Y; Brown, K; Marathi, R; Orkunoglu-Suer, FE; Devaney, JM; Leiken, B; Many, G; Krebs, J; Hopkins, WG; Hoffman, EP
Physiological genomics  46  747-65  2014

Show Abstract
25138607 25138607
Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis.
Noda, S; Asano, Y; Nishimura, S; Taniguchi, T; Fujiu, K; Manabe, I; Nakamura, K; Yamashita, T; Saigusa, R; Akamata, K; Takahashi, T; Ichimura, Y; Toyama, T; Tsuruta, D; Trojanowska, M; Nagai, R; Sato, S
Nature communications  5  5797  2014

Show Abstract
Immunohistochemistry25504335 25504335
Multiscale distribution and bioaccumulation analysis of clofazimine reveals a massive immune system-mediated xenobiotic sequestration response.
Baik, J; Stringer, KA; Mane, G; Rosania, GR
Antimicrobial agents and chemotherapy  57  1218-30  2013

Show Abstract
23263006 23263006
Endothelial Progenitors Exist within the Kidney and Lung Mesenchyme.
Sims-Lucas, S; Schaefer, C; Bushnell, D; Ho, J; Logar, A; Prochownik, E; Gittes, G; Bates, CM
PloS one  8  e65993  2013

Show Abstract
23823180 23823180
Autologous minced muscle grafts: a tissue engineering therapy for the volumetric loss of skeletal muscle.
Corona, BT; Garg, K; Ward, CL; McDaniel, JS; Walters, TJ; Rathbone, CR
American journal of physiology. Cell physiology  305  C761-75  2013

Show Abstract
23885064 23885064
Spatiotemporal control of vascular endothelial growth factor expression using a heat-shock-activated, rapamycin-dependent gene switch.
Martín-Saavedra, FM; Wilson, CG; Voellmy, R; Vilaboa, N; Franceschi, RT
Human gene therapy methods  24  160-70  2013

Show Abstract
23527589 23527589

Related Products & Applications

Related Products

Catalogue Number Description
05-861 Anti-vWF (von Willebrand Factor) Antibody, clone GMA-022

Product Families

Categories

Life Science Research > Antibodies and Assays > Primary Antibodies